Back to Search
Start Over
ER+/ HER2 -ve Breast Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BeiGene, Novartis, Pfizer, AstraZeneca, Roche, EQRx
- Source :
- M2 Presswire. October 12, 2023
- Publication Year :
- 2023
-
Abstract
- M2 PRESSWIRE-October 12, 2023-: ER+/ HER2 -ve Breast Cancer Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BeiGene, Novartis, Pfizer, AstraZeneca, Roche, EQRx [...]
- Subjects :
- Pfizer Inc. -- Product development -- Forecasts and trends
Novartis AG -- Product development -- Forecasts and trends
AstraZeneca PLC -- Forecasts and trends -- Product development
Business -- Research
Clinical trials -- Forecasts and trends
Breast cancer -- Forecasts and trends
Pharmaceutical industry -- Product development -- Forecasts and trends
Market trend/market analysis
Business
Business, international
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 Presswire
- Publication Type :
- News
- Accession number :
- edsgcl.768599943